摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(R)-1,3-Dimethylpiperazine dihydrochloride

中文名称
——
中文别名
——
英文名称
(R)-1,3-Dimethylpiperazine dihydrochloride
英文别名
(3R)-1,3-dimethylpiperazine;dihydrochloride
(R)-1,3-Dimethylpiperazine dihydrochloride化学式
CAS
——
化学式
C6H16Cl2N2
mdl
——
分子量
187.11
InChiKey
ADCWAVJWPWKDRK-QYCVXMPOSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.75
  • 重原子数:
    10
  • 可旋转键数:
    0
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    15.3
  • 氢给体数:
    3
  • 氢受体数:
    2

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] PEPTIDE DEFORMYLASE INHIBITORS<br/>[FR] INHIBITEURS DE LA PEPTIDE DÉFORMYLASE
    申请人:SMITHKLINE BEECHAM CORP
    公开号:WO2009061879A1
    公开(公告)日:2009-05-14
    The present invention is directed to certain 2-(alkyl)-3-[2-(5-fluoro-4-pyrimidinyl)hydrazino]-3-oxopropyl}hydroxyformamide derivatives, compositions containing them, the use of such compounds in the inhibition of bacterial peptide deformylase (PDF) activity, and in the treatment of bacterial infections. Specifically, the invention is directed to compounds of formula (I), wherein R1, R2 and R3 are defined herein and to pharmaceutically acceptable salts thereof. The compounds of this invention are bacterial peptide deformylase inhibitors and can be useful in the treatment of bacterial infections.
    本发明涉及某些2-(烷基)-3-[2-(5--4-嘧啶基)基]-3-氧代丙基}羟甲酰胺衍生物,含有它们的组合物,以及这些化合物在抑制细菌肽变形酶(PDF)活性和治疗细菌感染中的用途。具体而言,该发明涉及式(I)的化合物,其中R1、R2和R3在此有定义,并且其药用盐。本发明的这些化合物是细菌肽变形酶抑制剂,可用于治疗细菌感染。
  • [EN] JAK1 SELECTIVE INHIBITORS<br/>[FR] INHIBITEURS SÉLECTIFS DE JAK1
    申请人:ASTRAZENECA AB
    公开号:WO2018134213A1
    公开(公告)日:2018-07-26
    Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R1-R8 have any of the meanings defined herein. Also disclosed are pharmaceutical compositions comprising compounds of Formula (I) and methods of using the same.
    本文公开了式(I)的化合物及其药用盐,其中R1-R8具有本文中定义的任何含义。还公开了包含式(I)化合物的药物组合物以及使用这些药物的方法。
  • Peptide deformylase inhibitors
    申请人:GlaxoSmithKline LLC
    公开号:US07893056B2
    公开(公告)日:2011-02-22
    The present invention is directed to certain 2-(alkyl)-3-[2-(5-fluoro-4-pyrimidinyl)hydrazino]-3-oxopropyl}hydroxyformamide derivatives, compositions containing them, the use of such compounds in the inhibition of bacterial peptide deformylase (PDF) activity, and in the treatment of bacterial infections. Specifically, the invention is directed to compounds of formula (I): wherein R1, R2 and R3 are defined herein and to pharmaceutically acceptable salts thereof. The compounds of this invention are bacterial peptide deformylase inhibitors and can be useful in the treatment of bacterial infections.
    本发明涉及某些2-(烷基)-3-[2-(5--4-嘧啶基)基]-3-氧代丙基}羟基甲酰胺衍生物,含有它们的组合物,以及在抑制细菌肽变形酶(PDF)活性和治疗细菌感染方面使用这种化合物。具体而言,本发明涉及式(I)的化合物:其中R1、R2和R3在此定义,并且其药学上可接受的盐。本发明的化合物是细菌肽变形酶抑制剂,可用于治疗细菌感染。
  • 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE INHIBITORS OF PHD
    申请人:Takeda Phamaceutical Company Limited
    公开号:US20140296200A1
    公开(公告)日:2014-10-02
    The present invention provides compounds of the formula: which are useful as inhibitors of PHD, pharmaceutical compositions thereof, methods for treatment of conditions associated with HIF, processes for making the compounds and intermediates thereof.
    本发明提供了以下式子的化合物:该化合物可用作PHD的抑制剂,其制药组合物,用于治疗与HIF相关的疾病的方法,制备该化合物及其中间体的过程。
  • NOVEL COMPOUNDS
    申请人:BAYER PHARMA AKTIENGESELLSCHAFT
    公开号:US20160263122A1
    公开(公告)日:2016-09-15
    The present invention relates to substituted N-(phenyl-heteroaryl)-3-acetylamino-benzamides and N-[3-(acetylamino)phenyl]-phenyl-heteroaryl-carboxamides of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease such as cancer, wherein i.a.: L A represents an optionally substituted methylene or ethylene group; L B represents —N(H)—C(═0)- or —C(═0)—N(H)—; R 1 represents an optionally substituted 5- to 8-membered heterocycloalkyl, 4- to 10-membered heterocycloalkenyl, aryl, heteroaryl or —N(R7)(Ci-C6-alkyl) group; R 2 represents an optionally substituted 5- or 6-membered heteroaryl group; R 3 represents an optionally substituted phenyl group.
    本发明涉及一般式(I)所描述和定义的取代N-苯基-杂环基-3-乙酰基苯甲酰胺和N-[3-(乙酰基)苯基]-苯基-杂环基-羧酰胺,以制备该化合物的方法,用于制备该化合物的中间体化合物,包含该化合物的制药组合物和组合物,以及用于制造治疗或预防癌症等疾病的制药组合物的使用,其中:LA表示可选择取代的亚甲基或乙烯基;LB表示-N(H)-C(═0)-或-C(═0)-N(H)-;R1表示可选择取代的5-至8-成员杂环烷基,4-至10-成员杂环烷基烯基,芳基,杂环芳基或-N(R7)(Ci-C6-烷基)基团;R2表示可选择取代的5-或6-成员杂环基团;R3表示可选择取代的苯基团。
查看更多